Carbon Chemist

Tag: Clinical pharmacology

  • Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

    [ad_1]

    Human genetics assessment

    Population cohorts

    We included 453,072 participants in the UK Biobank, 164,353 participants in Geisinger Health System MyCode cohort, 41,251 participants in the Penn Medicine Biobank (UPENN-PMBB), 28,935 participants in the Malmö Diet and Cancer Study, 26,035 participants in the Mount Sinai BioMe Biobank and 4,736 participants recruited from Indiana University School of Medicine32,33. Systolic and diastolic BP readings were obtained from participants in the UK Biobank, Geisinger Health System MyCode cohort, UPENN-PMBB and the Malmö Diet and Cancer Study. In case of more than one BP reading, we used the median value. To correct for treatment with anti-hypertensive medication, 15 mm Hg was added to systolic BP readings and 10 mm Hg to diastolic BP readings in individuals with a history of treatment with anti-hypertensive medication, as previously done34,35. NT-proBNP was measured in the UK Biobank using a proteomics assay Olink36; in the Geisinger Health System MyCode cohort, measurements were extracted from electronic health records. HF was defined on the basis of International Classification of Diseases codes and procedure codes obtained from electronic health records as summarized in Supplementary Table 6.

    DNA sequencing and genotyping data

    The Regeneron Genetics Center performed high-coverage whole-exome sequencing using NimbleGen VCRome probes (Roche) or a modified version of the xGen design from Integrated DNA Technologies (IDT). Sequencing was performed using the Illumina v4 HiSeq 2500 or NovaSeq instrument, achieving over 20× coverage for 96% of VCRome samples and 99% of IDT samples. Variants were annotated using snpEff and Ensembl v85 gene definitions, prioritizing protein-coding transcripts on the basis of functional impact. The following variants were defined as protein truncating: insertions or deletions resulting in frameshift, any variant causing a stop gained, start lost or stop lost and any variants affecting a splice acceptor or splice donor site. Common-variant genotyping was performed on one of three single-nucleotide polymorphism array types as previously described: Illumina OmniExpress Exome array, Applied Biosystems UK BiLEVE Axiom Array or Applied Biosystems UK Biobank Axiom Array. We retained genotyped variants with a minor allele frequency (MAF) of >1%, <10% missingness and Hardy–Weinberg equilibrium test P > 10−15. We imputed the genotyped variants using the TOPMed reference panel37 using the TOPMed imputation server38,39. In GHS, imputation was performed separately by genotyping platform. Further details are provided elsewhere32,33,40,41.

    Association analyses

    We estimated associations between protein-altering variants in NPR1 and phenotypes by fitting additive genetic, linear regression models (for quantitative traits; BP and NT-proBNP) or Firth bias-corrected logistic regression models (for binary traits; HF) using REGENIE (v.2+) software42. Analyses were stratified according to ancestry and were adjusted for age, age squared, sex, age-by-sex and age squared-by-sex interaction terms; experimental batch-related covariates; the first 10 common-variant–derived genetic principal components; the first 20 rare-variant-derived principal components; and a polygenic score generated by REGENIE, which robustly adjusts for relatedness and population structure42. Association results were meta-analysed across cohorts and ancestries using fixed-effects inverse variance weighting.

    In addition to analysing individual protein-altering variants in NPR1, we evaluated two sets of gene-based burden genotypes: (1) a collection of rare predicted LOF variants; and (2) collections that include rare missense variants that are predicted to be GOF or LOF on the basis of experimental evidence or their association with BP. To characterize GOF or LOF, we first tested for association of rare and low-frequency (MAF < 1%), protein-truncating variants (presumed LOF) in NPR1 with BP and NT-proBNP across all available samples. Second, after exclusion of individuals with HF, we randomly split the cohorts with available BP readings in half into training sets (half of the samples) and test sets (half of the samples). All protein-altering variants in NPR1 with MAF < 1% and a minor allele count of ≥10 associated with increased systolic or diastolic BP (P < 0.05) in the training set were characterized as presumed LOF, whereas variants associated with decreased systolic or diastolic BP in the training set were characterized as presumed GOF. The three previously published LOF or GOF variants15 were included regardless of these variant selection criteria. We then tested for association of the burden of presumed GOF and LOF variants with BP in the test sets and with NT-proBNP and HF in the combined set of test set samples and HF samples.

    Generation of REGN5381

    Fully human monoclonal antibodies against NPR1 were generated using VelocImmune technology21,22. The VelocImmune platform uses mice that are genetically modified to produce antibodies with human variable regions and enables efficient selection and development of fully human antibodies. Mice were immunized by the co-injections of human NPR1 and mouse ANP-expressing DNA plasmids, boosted with a protein complex of ANP–hNPR1. From the high-titre mice, splenocytes were isolated, and clones producing antibodies with desirable properties were identified and cloned to produce recombinant antibody proteins.

    Surface plasmon resonance binding

    The kinetics of REGN5381 NPR1-specific monoclonal antibody binding to NPR1 proteins were determined on the Biacore 8K, Biacore 4000, T200 or S200 biosensor (Cytiva), using the Series S CM4 sensor chip in filtered and degassed HEPES-buffered saline running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.05% (v/v) polysorbate 20, pH 7.4) at 25 °C or 37 °C. The CM4 sensor chip was immobilized with mouse anti-human fragment crystallizable region (Fc) monoclonal antibody (REGN2567) or mouse anti-His monoclonal antibody (Cytiva) using standard amine-coupling chemistry43. REGN5381 NPR1 monoclonal antibodies were captured (100 RU-685 RU) through their Fc regions on anti-human Fc immobilized surfaces and varying concentrations of extracellular domains of NPR1, NPR2 and NPR3 proteins (with C-terminal MycMycHis) and ANP were injected followed by a dissociation phase. At the end of each cycle, anti-human-Fc-captured NPR1-specific monoclonal antibodies were removed using a 12 s injection of 20 mmol l−1 phosphoric acid.

    All of the specific surface plasmon resonance-binding sensorgrams were double-reference-subtracted as reported previously44, and the kinetic parameters were obtained by globally fitting the double-reference-subtracted data to a 1:1 binding model with mass transport limitation using Biacore Insight Evaluation software (Cytiva). The dissociation rate constant (kd) was determined by fitting the change in the binding response during the dissociation phase, and the association rate constant (ka) was determined by globally fitting analyte binding at different concentrations. The equilibrium dissociation constant (KD) was calculated from the ratio of kd and ka. The dissociative half-life in minutes was calculated as ln2/(kd × 60).

    Cell binding and NPR1 bioassays

    HEK293 cell lines were generated to stably express hNPR1 (amino acids M1 to G1061 of NP_000897.3) with C-terminal MYC and Flag tags or mfNPR1 (amino acids M1 to G1061 of XP_005541809.1). Flow cytometry experiments were performed with antibodies with or without 100 nM of human ANP or BNP (CytoFLEX flow cytometer) and the results were analysed using FlowJo. To assess NPR1 activity, bovine CNGA2 (amino acids Met1 to Pro663 of UniProt Q03041) was expressed along with NPR1. CNGA2 is a cation channel that can be activated by cGMP and can therefore be used as a readout for cGMP production23. NPR1 activation was monitored by measuring calcium influx through CNGA2 using a fluorescent Ca2+ indicator (Invitrogen Fluo-4 Direct Calcium Assay Kit; FLIPR TETRA, Molecular Devices). The numeric Ca2+ flux signal (one read per s, 700 total), expressed in relative fluorescence units, was calculated as the area under the time-signal-intensity curve from which the background signal observed before the addition of test reagents was subtracted. NPR1 activity was also evaluated by cGMP production (Cisbio cGMP kit, 62GM2PEH) with REGN5381 in the absence or presence of ligand at either 37 °C with 20,000 cells or room temperature with 1,000 cells. HEK293 cells have been authenticated via Human 16-Marker STR profile (IDEXX BioAnalytics) to be >80% identical to HEK293 cells sourced from ATCC, and tested negative for mycoplasma.

    Physical complex assessment

    A4F-MALS was used to assess the relative size distribution of complexes formed between REGN5381, hNPR1 ectodomain (REGN3037) and ANP. The A4F-MALS system is composed of a Wyatt Eclipse instrument and channel coupled to an Agilent 1260 Series High Performance Liquid Chromatography system equipped with an ultraviolet (UV) diode array detector, Wyatt Technology DAWN laser light-scattering (LS) instrument and an Optilab T-rEX differential refractometer (RI) detector. The detectors were connected in series in the following order: UV–LS–RI. The detector flow was maintained at 1.0 ml min−1 for the duration of the run, and the samples were injected onto the channel at 0.2 ml min−1 and were focused for 3 min using a focus flow rate of 1.5 ml min−1. The separation step consisted of a linear gradient of the crossflow from 2.0 ml min−1 to 0.0 ml min−1 over 45 min before holding the crossflow for a further 5 min at 0.0 ml min−1 to allow any large particles to elute. The spacer in the channel was 350 W (Wyatt, 350 Å in height) while the membrane was 10 kDa MWCO regenerated cellulose (Wyatt). The mobile phase for all experiments was 10 mM sodium phosphate and 500 mM NaCl pH 7.0 ± 0.1.

    Cryo-EM analysis

    Sample preparation and data collection

    The NPR1 soluble domain was mixed with molar excess of the Fab fragment of REGN5381 in the presence or absence of ANP. The complex was incubated overnight at 4 °C then purified over the Superdex 200 increase 10/300 GL gel-filtration column equilibrated with 50 mM Tris pH 7.5 and 150 mM NaCl. Peak fractions containing the NPR1-REGN5381 Fab complex were collected and concentrated using a 10 kDa molecular weight cut-off centrifugal concentrator (Amicon). For cryo-EM grid preparation, the protein sample was diluted to 1.6 mg ml−1 and 0.15% poly(maleic anhydride-alt-1-decene)-C8 amphipol was added. Then, 3 µl of protein was deposited onto a freshly plasma cleaned UltrAufoil grid (0.6/1, 300 mesh) using the Gatan Solarus II (Gatan) system. Excess solution was blotted away using filter paper and plunge-frozen into liquid ethane using the Vitrobot Mark IV (Thermo Fisher Scientific). The cryo-EM grid was transferred to a Titan Krios (Thermo Fisher Scientific) operated at 300 kV and equipped with a K3 detector (Gatan). Automated data collection was carried out using EPU (Thermo Fisher Scientific) at a nominal magnification of ×105,000, corresponding to a pixel size of 0.86 Å. A dose rate of 15 e− px−1 s−1 was used and each video was 2 s, corresponding to a total dose of around 40 e− Å−2. The defocus ranged from −1.4 to −2.4 µm.

    NPR1–REGN5381 Fab–ANP complex

    All cryo-EM data processing was performed using cryoSPARC (v.3.2.0)45. A total of 6,717 videos were collected; after alignment using patch motion correction followed by patch contrast transfer function estimation, 6,313 videos were selected for particle picking. An initial set of particles picked using a blob picker were subjected to 2D classification to generate templates for template picking (Extended Data Fig. 4a–c). In total, around 1.16 million particles picked by template picking were subjected to multiple rounds of 2D classification, yielding around 1.04 million particles in the optimal classes. Ab initio reconstruction with six classes generated different states of the NPR1 dimer with the REGN5381 Fab; the highest-resolution class had 682,951 particles corresponding to an NPR1 dimer with two REGN5381 Fabs and ANP bound. Non-uniform refinement of the particles in this class, followed by local refinement, resulted in a 3.1-Å-resolution (Fourier shell correlation = 0.143) map that was used for model building. Into this map, we manually placed models of NPR1 dimer in complex with ANP (PDB: 1T34) and two Fabs (derived from other Regeneron antibody structures). These models were then manually rebuilt using Coot46, and real-space refined against the map using Phenix47. Cryo-EM data and model statistics are provided in Extended Data Table 1.

    NPR1–REGN5381 Fab complex (no ANP)

    For this complex, a total of 6,541 videos were collected; after alignment using patch motion correction followed by patch contrast transfer function estimation, 6,324 videos were selected for particle picking. An initial set of particles picked using a blob picker were subjected to 2D classification to generate templates for template picking (Extended Data Fig. 4d–f). In total, around 1.3 million particles picked by template picking were subjected to multiple rounds of 2D classification, yielding about 0.96 million particles in the optimal classes. Ab initio reconstruction with three classes generated different states of the NPR1 dimer with the REGN5381 Fab; the highest resolution class had 495,382 particles corresponding to an NPR1 dimer with two REGN5381 Fabs and ANP bound. Non-uniform refinement of the particles in this class, followed by local refinement, resulted in a 3.65-Å-resolution (Fourier shell correlation = 0.143) map. This dataset has substantial preferred particle orientation, and the map resolution is anisotropic and, in many areas, a good deal worse than 3.65 Å (Extended Data Fig. 4d). Although this map clearly defined the overall conformation of the NPR1–REGN5381 complex, and showed no density at the ANP-binding site (Extended Data Fig. 4d), it was not feasible to carry out model building and refinement in the manner that we did for the NPR1–REGN5381–ANP complex. Instead, that complex model was split into two half-complex models, each containing one NPR1 ectodomain and one REGN5381 Fab. These half-complexes were rigid-body refined against the NPR1–REGN5381 (no ANP) map using Phenix47, producing the model shown in Fig. 2. Cryo-EM data and model statistics are provided in Extended Data Table 1.

    Preclinical in vivo mouse studies

    NPR1
    hu/hu mice

    NPR1hu/hu mice were generated on the C57BL/6NTac (75%)/129S6SvEvTac (25%) background using the Velocigene platform48. The generation of these mice was necessitated by the poor conservation of the NPR1 amino acid sequence between human and mouse, and the need to generate a human antibody. Each animal was implanted with PA-C10 (Data Sciences) radiotelemetry devices for the recording of central arterial pressures. The transmitter was located in the carotid artery of each mouse.

    All of the mouse experiments were conducted in compliance with protocols approved by the Regeneron Pharmaceuticals Institutional Animal Care and Use Committee, in accordance with state and federal guidelines. Mice were fed normal chow (PicoLab Rodent Diet 20, 5001), housed under standard conditions and allowed to acclimatize for at least 7 days before being placed on the study.

    REGN5381 was diluted with sterile phosphate-buffered saline for subcutaneous injection into mice.

    REGN5381 single-dose mouse study

    Telemetered NPR1hu/hu mice were randomly assigned to one of five dosing groups (n = 4–6 per group) on the basis of body weight, and received a single subcutaneous dose of saline or REGN5381 (1, 5, 25 or 50 mg per kg) on study day 0. The BP of each animal was continuously monitored for 28 days. Urine samples for urinalysis and urinary biomarkers were collected on day 28 after dosing.

    REGN5381 versus standard-of-care therapies

    Comparisons of REGN5381 alone and in combination with standard-of-care therapies were conducted as a series of four separate experiments. For each experiment, telemetered NPR1hu/hu mice were stratified by systolic BP into one of four dosing groups (n = 5–7 per group). The groups then received a single subcutaneous dose of saline or REGN5381 (25 mg per kg), immediately followed by an oral gavage dose of water or standard-of-care therapy (enalapril 25 mg per kg per day; valsartan 125 mg per kg per day; sacubitril 120 mg per kg per day; sildenafil 40 mg per kg per day; milrinone 5 mg per kg per day; propranolol 5 mg per kg per day; nifedipine 20 mg per kg per day; sacubitril/valsartan 100 mg per kg; empagliflozin 30 mg per kg; spironolactone 100 mg per kg). Oral dosing continued once daily in the morning for 7 days. The dose volume for each animal was based on the most recent body weight measurement. Each animal’s BP was continuously monitored for 7 days.

    Ex vivo vessel reactivity

    NPR1hu/hu mice were euthanized by CO2 inhalation followed by laparotomy. The abdominal aorta, third-order mesenteric arteries and mesenteric vein were dissected. Arterial and vein segments (~2 mm in length) were placed into ice-cold Krebs buffer solution and prepared for wire myography. Vascular rings were mounted onto wires in the chambers of a multivessel myograph (J P Trading) filled with Krebs buffer maintained at 37 °C (refs. 49,50,51). The buffer was gassed with 95% O2–5% CO2. After equilibration for 30–60 min, the vessels were set to an internal circumference equivalent to 90% of what they would be in vivo when relaxed under an intraluminal pressure of 100 mm Hg (ref. 49). Isometric tension was monitored continuously before and after experimental interventions and was expressed as mN mm−1 vessel length. The experiments were initiated after a 30–60 min stabilization interval. In each vessel, the constrictor response to 80 mmol l−1 KCl was determined. Vessels were precontracted with phenylephrine (10 × 10−6 mol l−1), and the vasodilatory response to acetylcholine or test article was measured. Data were expressed as mean ± s.e.m. Concentration–response data derived from each vessel was fitted separately to a logistic function by nonlinear regression, and the maximum asymptote of the curve (maximal response) and concentration of agonist producing EC50 were calculated using commercially available software (GraphPad Prism v.9.0.2). Concentration–response data were analysed using two-way analysis of variance followed by Tukey’s test. All other data were analysed using one-way analysis of variance or the Student’s t-tests for unpaired samples.

    Non-human primate pharmacodynamic study

    Thirty cynomolgus monkeys (Macaca fascicularis) of Mauritius origin, 2–4 years of age and weighing 3–5 kg (Charles River Laboratories), were enrolled in the study. Each animal was implanted with PhysioTel Digital model L11 (Data Sciences International) radiotelemetry devices for recording the central arterial pressure and ECG waveforms. The transmitter was located intramuscularly in a dorsal position and lateral to the median plane below the ribs, and the attached BP catheter was located in the femoral artery with the tip of the catheter located in the descending aorta.

    The animals were acclimatized to laboratory housing for a minimum of 5 weeks before initiation of dosing (including recovery time after surgical implantation when performed). During treatment, non-human primates were housed individually in stainless-steel cages in a controlled environment under standard conditions. They were provided Purina Certified Primate Diet 5048 biscuits twice daily and assorted fresh fruit or vegetables. Reverse-osmosis-filtered water was provided ad libitum by means of an automatic watering system. All non-human primate experiments were conducted in compliance with protocols approved by the Charles River Institutional Animal Care and Use Committee, in accordance with state and federal guidelines.

    Telemetered animals were randomly assigned to one of six dosing groups (n = 5 per group) and received a single subcutaneous dose of saline or REGN5381 (1, 5 or 25 mg per kg bolus), or a single intravenous dose of REGN5381 (5 or 25 mg per kg bolus) on study day 1. Each animal’s BP was continuously monitored for 28 days, and thereafter once weekly for 24 h until the completion of the study on day 56. Urine samples for urinalysis and urinary biomarkers were collected from a cage pan in the morning at baseline and 24 h after dosing. Blood samples for clinical chemistry and the determination of systemic REGN5381 concentrations in the serum were collected from all animals before dosing, and on days 2, 3, 4, 7, 14, 28, 42 and 56 after dosing. Blood samples collected at predose and on day 56 were also analysed for ADA. Concentrations of total REGN5381 (all drugs; without regard to binding site occupancy) were determined using an enzyme-linked immunosorbent assay. ADA analysis was conducted using a generic immunoassay against anti-human IgG4 antibodies.

    Canine telemetry study

    Two beagle canines (Canis lupus familiaris) 8–10 months of age and weighing 9–10.5 kg were received from Marshall BioResources and enrolled in the study. For telemetry studies, each animal was implanted with PhysioTel Digital model D70 (Data Sciences) radiotelemetry devices for recording the central arterial pressure.

    Animals were acclimatized to the laboratory housing for a minimum of 2 weeks before initiation of dosing (including recovery time after surgical implantation when performed). During treatment, canines were housed in groups of two in a controlled environment under standard conditions. They were provided PMI Nutrition international Certified Canine LabDiet 5007 daily. Reverse-osmosis-filtered water was provided ad libitum. All canine experiments were conducted in compliance with protocols approved by the Charles River Institutional Animal Care and Use Committee, in accordance with state and federal guidelines.

    A cross-over design was used, and each canine received a single intravenous bolus dose of saline (control, n = 2), followed by a 7-day washout period. Canines then received a single intravenous slow bolus of 25 mg per kg REGN5381 (n = 2). Radiotelemetry data were acquired continuously, beginning 48 h before the first administration of vehicle or REGN5381, and continued for 48 h after dosing.

    Acute anaesthetized canine study

    Twelve beagle canines (C. l. familiaris) 11–13 months of age and weighing 9–15 kg were received from Covance and enrolled in the study. General procedures for animal care and housing met current American Association for Accreditation of Laboratory Animal Care International recommendations, Guide for the Care and Use of Laboratory Animals and the US Department of Agriculture through the Animal Welfare Act (as amended, and conformed to testing facility SOP)52,53. Canines were housed in runs (up to two canines per run). The temperature and humidity ranges of the study room were set to maintain 74 ± 10 °F and 50 ± 20%, respectively. The light cycle was set to maintain 12 h–12 h on–off. Canines were offered Certified Canine Diet (LabDiet 5007) once daily except on the day of that canine’s scheduled experiment; each canine was kept on an overnight fast before the day of its scheduled experiment. Canines were provided with fresh water ad libitum using an automatic watering system except when removed from the run. Anaesthetized canines were instrumented with venous and arterial catheters. Each canine received a single intravenous bolus dose of saline (control, n = 6) or 25 mg per kg REGN5381 (n = 6). Following dose administration, canines were monitored for acute haemodynamic changes.

    Before dose administration, each canine was anaesthetized and instrumented for cardiovascular data collection. After placement of all cardiovascular instrumentation, each canine had baseline haemodynamic parameters collected before dosing while they were anaesthetized. Each dose was administered as a single intravenous bolus to the animal. Dose volumes were based on each canine’s most recent individual body weight. After dose administration, the animals were monitored for acute haemodynamic changes. Throughout each experiment, blood and urine samples, as well as haemodynamic parameters, were collected.

    Canine surgical catheter implantation

    A minimum of two venous catheters were placed into a peripheral vessel (for example, cephalic and/or saphenous) for administration of anaesthetics and analgesics. General anaesthesia was induced intravenously (bolus) with propofol (approximately 6 mg per kg) and α-chloralose (30–100 mg per kg), aided by fentanyl (approximately 5 µg per kg). A cuffed endotracheal tube was placed and used to mechanically ventilate the lungs with up to 100% O2 through a volume-cycled animal ventilator (10–15 breaths per min with a tidal volume of 15–30 ml per kg) to sustain end-tidal expired CO2 values within the normal physiological range (35–45 mm Hg). Anaesthesia was maintained by intravenous infusion of α-chloralose (20–55 mg per kg per h), with analgesia provided by intravenous infusion of fentanyl (2.0–10.0 µg per kg per h) to preserve normal autonomic function, as well as inotropic/lusitropic properties. Fentanyl and α-chloralose infusions ran concurrently through the same, single peripheral venous catheter. The second venous catheter was used for dosing of control/test article. Surface electrodes were placed onto the thorax for the recording of body-surface ECGs (for example, Lead II). The body temperature was maintained within the normal physiological range by temperature-controlled warming blankets.

    Local anaesthesia (bupivacaine 0.5%, 1–2 ml per site) was administered subcutaneously over each surgical site before surgical manipulation. Once a surgical plane of anaesthesia was achieved, a cut-down over a jugular vein and carotid artery was performed for placement of fluid-filled introducers. Two vessel introducers were secured within the jugular vein/jugular vein branches. Through one of the jugular access catheters, a flow-directed Swan Ganz sampling catheter was advanced into the pulmonary artery for the determination of pulmonary artery pressures, right atrial pressures/CVPs. Through the carotid artery, a catheter was advanced into the left ventricle for assessment of left ventricular pressure. A cut-down over the femoral triangle was used to access the femoral artery and vein. A fluid-filled introducer was secured within the femoral artery; through this femoral artery introducer, a solid-state pressure transducer was advanced into the artery to collect an arterial pressure waveform.

    ANP and BNP expression constructs

    The mouse BNP hydrodynamic delivery construct was constructed by ligating synthetic DNA constructs (Genscript) containing the Nppb coding sequences through the BglII–NotI restriction sites into the vector pRG977-mRor-V5 (N-term.) to create the final constructs used for injection into mice. The reference sequence used in the design of the expression construct was mouse Nppb reference protein (NCBI: NP_032752). The mouse ANP hydrodynamic delivery construct was constructed by ligating synthetic DNA constructs (Genscript) containing the Nppa coding sequences into the vector pRG977 to create the final constructs used for injection into mice. The reference sequence used in the design of the expression construct was mouse Nppa reference protein (NP_032751). On study day 0, mice were stratified into groups on the basis of body weight. Mice were injected through the tail vein with 50 µg plasmid in sterile saline at 10% of body weight.

    Clinical study

    REGN5381 in a first-in-human study

    A phase 1, double-blind, placebo-controlled, two-part single-ascending dose study was designed to assess the safety, tolerability and pharmacodynamics/pharmacokinetics of REGN5381 in healthy adults (18–55 years of age; NCT04506645). Data reported here include only findings from the first part, which was conducted in healthy adults (18–55 years of age) at a single site. The study protocol was approved by institutional review boards or relevant ethics committee, and the research ethics committee of the University Hospitals of Leuven. The study was conducted in accordance with the ethical principles originating from the Declaration of Helsinki, and was consistent with the International Conference on Harmonization/Good Clinical Practices and applicable regulatory requirements. All of the participants provided written informed consent.

    Participants were screened for systolic BP 100–140 mm Hg (inclusive) and diastolic BP 60–90 mm Hg (inclusive). If the participants in a dosing cohort experienced clinically important hypotension or tachycardia, the BP inclusion criteria could be adapted to allow for increases in the range (systolic BP, 130–165 mm Hg; diastolic BP, 60–100 mm Hg), although adaptation of the inclusion criteria was not necessary. After initial screening, the participants attended a 2-day inpatient treatment/observation period before dosing and were placed on a fixed-sodium diet to ensure consistency in sodium intake and to reduce the variability in BP due to dietary sodium. Non-invasive haemodynamics were measured using pulse-wave analysis technology (ClearSight, Edwards Lifesciences) beginning 1 day before randomization and continued through to the end of the inpatient monitoring period.

    The participants were randomized 6:2 to receive single-dose intravenous REGN5381 (0.3, 1, 3, 10, 30 or 100 mg) or intravenous placebo. After study drug administration on day 1, the participants remained in the clinic until day 4 to allow careful monitoring of haemodynamics. On day 4, the participants were assessed for safety before discharge. The study duration was based on predicted blood levels of REGN5381 concentrations in the serum across all dose cohorts; the end of the study visit was conducted no earlier than 21 days after the administration of the study drug. The primary end point in this study was the type, incidence and severity of TEAEs after a single intravenous dose administration of REGN5381 or placebo over time.

    Statistical analyses

    Preclinical assessments

    Statistical analysis was performed using standard statistical software (GraphPad Prism 7). Analysis of data were performed using one-way analysis of variance or two-way repeated-measures analysis of variance. Tukey’s post hoc multiple-comparison test (α = 0.05) was used. Data are reported as mean ± s.e.m. P < 0.05 was considered to be significant.

    First-in-human clinical assessments

    There was no formal primary efficacy analysis in this study. For continuous variables, descriptive statistics included the following information: the number of participants reflected in the calculation (n), mean, s.d., quartile 1, quartile 3, median, minimum and maximum. Plots of the values over time, as well as the change or percentage change over time, were provided.

    Haemodynamic parameters are known to be sensitive to the nominal time of the day; for example, a participant may have a relatively higher BP during the daytime than at night. Thus, a time-matched change from baseline in systolic BP, diastolic BP, mean arterial pressure, pulse pressure and cardiac stroke volume across the first 24 h after dose was reported by treatment group. For example, the time-matched change from baseline at 07:00 was calculated as follows:

    $${{\rm{Chg}}}_{07:00}={{\rm{BP}}}_{{\rm{07:00\; D1}}}-{{\rm{BP}}}_{{\rm{07:00\; D-1}}}$$

    where BP07:00 D1 was the BP collected at 07:00 on day 1 and BP07:00 D−1 was the blood pressure collected at 07:00 on day −1. Time-matched mean change from the baseline for the pulse-wave analysis was provided by treatment group.

    For categorical or ordinal data, frequencies and percentages were displayed for each category. Unless otherwise specified, the participants randomized to placebo were pooled across cohorts.

    Reporting summary

    Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

    [ad_2]

    Source link

  • Targeting hypoxia-inducible factors: therapeutic opportunities and challenges

    [ad_1]

  • Taylor, C. T. & McElwain, J. C. Ancient atmospheres and the evolution of oxygen sensing via the hypoxia-inducible factor in metazoans. Physiology 25, 272–279 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Mills, D. B. et al. The last common ancestor of animals lacked the HIF pathway and respired in low-oxygen environments. eLife 7, e31176 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Semenza, G. L., Roth, P. H., Fang, H. M. & Wang, G. L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269, 23757–23763 (1994).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Liu, Y., Cox, S. R., Morita, T. & Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77, 638–643 (1995).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Poth, J. M., Brodsky, K., Ehrentraut, H., Grenz, A. & Eltzschig, H. K. Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease. J. Mol. Med. 91, 183–193 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Eltzschig, H. K., Sitkovsky, M. V. & Robson, S. C. Purinergic signaling during inflammation. N. Engl. J. Med. 367, 2322–2333 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Prabhakar, N. R. & Semenza, G. L. Adaptive and maladaptive cardiorespiratory responses to continuous and intermittent hypoxia mediated by hypoxia-inducible factors 1 and 2. Physiol. Rev. 92, 967–1003 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Semenza, G. L. Oxygen sensing, homeostasis, and disease. N. Engl. J. Med. 365, 537–547 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Eckle, T. et al. Adora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia. Nat. Med. 18, 774–782 (2012). This study reports that adenosine-dependent Per2 stabilization facilitates HIF-elicited cardiac metabolic adaptation and ischaemia tolerance.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K. & Eckle, T. Ischemia and reperfusion — from mechanism to translation. Nat. Med. 17, 1391–1401 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Lee, P., Chandel, N. S. & Simon, M. C. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat. Rev. Mol. Cell Biol. 21, 268–283 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Smith, T. G., Robbins, P. A. & Ratcliffe, P. J. The human side of hypoxia-inducible factor. Br. J. Haematol. 141, 325–334 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Manalo, D. J. et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105, 659–669 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Neudecker, V., Yuan, X., Bowser, J. L. & Eltzschig, H. K. MicroRNAs in mucosal inflammation. J. Mol. Med. 95, 935–949 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Neudecker, V., Brodsky, K. S., Kreth, S., Ginde, A. A. & Eltzschig, H. K. Emerging roles for microRNAs in perioperative medicine. Anesthesiology 124, 489–506 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ju, C. et al. Hypoxia-inducible factor-1alpha-dependent induction of miR122 enhances hepatic ischemia tolerance. J. Clin. Invest. 131, e140300 (2021). This paper demonstrates that miRNAs can function in feed-forward loops by repressing PHDs, thereby enhancing their transcriptional induction through HIFs and providing tissue protection during liver ischemia–reperfusion injury.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wang, G. L. & Semenza, G. L. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 268, 21513–21518 (1993).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Semenza, G. L., Nejfelt, M. K., Chi, S. M. & Antonarakis, S. E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl Acad. Sci. USA 88, 5680–5684 (1991). This study is among the first reports from the Nobel laureate Gregg Semenza to describe a novel protein as a HIF that functions as a transcriptional enhancer of EPO.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Semenza, G. L., Koury, S. T., Nejfelt, M. K., Gearhart, J. D. & Antonarakis, S. E. Cell-type-specific and hypoxia-inducible expression of the human erythropoietin gene in transgenic mice. Proc. Natl Acad. Sci. USA 88, 8725–8729 (1991).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fandrey, J., Schodel, J., Eckardt, K. U., Katschinski, D. M. & Wenger, R. H. Now a nobel gas: oxygen. Pflug. Arch. 471, 1343–1358 (2019).

    Article 
    CAS 

    Google Scholar     

  • Ivan, M. et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001). This study reports the identification of VHL tumour suppressor protein as a key molecule in the oxygen-dependent degradation of HIFα.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jaakkola, P. et al. Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43–54 (2001). This study describes EGL9 as a key dioxygenase for oxygen-dependent HIF prolyl hydroxylation in C. elegans and defined isoforms of conserved HIF-PHDs in mammalian cells.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Eltzschig, H. K. et al. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202, 1493–1505 (2005).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K. et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104, 3986–3992 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Thompson, L. F. et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200, 1395–1405 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K. et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J. Exp. Med. 198, 783–796 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wicks, E. E. & Semenza, G. L. Hypoxia-inducible factors: cancer progression and clinical translation. J. Clin. Invest. 132, e159839 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K. & Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 364, 656–665 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Bowser, J. L., Lee, J. W., Yuan, X. & Eltzschig, H. K. The hypoxia–adenosine link during inflammation. J. Appl. Physiol. 123, 1303–1320 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eckle, T. et al. HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol. 11, e1001665 (2013). This study demonstrates that HIF1α is stabilized in the lungs during ARDS, and functions in endogenous lung protection by optimizing glucose metabolism in alveolar epithelial cells.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Bartels, K., Grenz, A. & Eltzschig, H. K. Hypoxia and inflammation are two sides of the same coin. Proc. Natl Acad. Sci. USA 110, 18351–18352 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Karhausen, J. et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114, 1098–1106 (2004).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Clambey, E. T. et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl Acad. Sci. USA 109, E2784–E2793 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Campbell, E. L. et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 40, 66–77 (2014). This study shows that infiltrating neutrophils deplete local oxygen to stabilize HIF and promote intestinal inflammation resolution in murine colitis models.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K., Bratton, D. L. & Colgan, S. P. Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases. Nat. Rev. Drug. Discov. 13, 852–869 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hatfield, S. M. et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med. 7, 277ra230 (2015).

    Article 

    Google Scholar     

  • Lee, J. W., Ko, J., Ju, C. & Eltzschig, H. K. Hypoxia signaling in human diseases and therapeutic targets. Exp. Mol. Med. 51, 1–13 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ong, S. G. et al. HIF-1 reduces ischaemia-reperfusion injury in the heart by targeting the mitochondrial permeability transition pore. Cardiovasc. Res. 104, 24–36 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Guo, Y. et al. Systematic review with meta-analysis: HIF-1alpha attenuates liver ischemia-reperfusion injury. Transpl. Rev. 29, 127–134 (2015).

    Article 

    Google Scholar     

  • Gao, R. Y. et al. Hypoxia-inducible factor-2alpha reprograms liver macrophages to protect against acute liver injury through the production of interleukin-6. Hepatology 71, 2105–2117 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kapitsinou, P. P. et al. Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury. J. Clin. Invest. 124, 2396–2409 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hill, P. et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39–46 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Woods, P. S. et al. HIF-1alpha induces glycolytic reprograming in tissue-resident alveolar macrophages to promote cell survival during acute lung injury. eLife 11, e77457 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kim, Y. I. et al. Local stabilization of hypoxia-inducible factor-1alpha controls intestinal inflammation via enhanced gut barrier function and immune regulation. Front. Immunol. 11, 609689 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Dowdell, A. S. et al. The HIF target ATG9A is essential for epithelial barrier function and tight junction biogenesis. Mol. Biol. Cell 31, 2249–2258 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lin, A. E. et al. Role of hypoxia inducible factor-1alpha (HIF-1alpha) in innate defense against uropathogenic escherichia coli infection. PLoS Pathog. 11, e1004818 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Bhandari, T. & Nizet, V. Hypoxia-inducible factor (HIF) as a pharmacological target for prevention and treatment of infectious diseases. Infect. Dis. Ther. 3, 159–174 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Suhara, T. et al. Inhibition of the oxygen sensor PHD2 in the liver improves survival in lactic acidosis by activating the Cori cycle. Proc. Natl Acad. Sci. USA 112, 11642–11647 (2015). This study shows that PHD2 is a novel therapeutic target for lactic acidosis and indicates that pharmacological enhancement of PHD2 might benefit infectious and ischaemic diseases.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Sanghani, N. S. & Haase, V. H. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv. Chronic Kidney Dis. 26, 253–266 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eckardt, K. U. et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N. Engl. J. Med. 384, 1601–1612 (2021). This study reports two randomized, phase III clinical trials that showed that HIF-PHDi vadadustat was non-inferior to darbepoetin alfa in cardiovascular safety and efficacy in correcting anaemia in patients with CKD undergoing dialysis.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Chertow, G. M. et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N. Engl. J. Med. 384, 1589–1600 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Chen, N. et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. 381, 1001–1010 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Chen, N. et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N. Engl. J. Med. 381, 1011–1022 (2019). This study reports the results from a randomized and multicentre phase III clinical trial that showed that HIF-PHDi roxadustat was noninferior to parenteral epoetin alfa in correcting anaemia in Chinese patients undergoing dialysis.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhou, J. & Gong, K. Belzutifan: a novel therapy for von Hippel-Lindau disease. Nat. Rev. Nephrol. 18, 205–206 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jonasch, E. et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N. Engl. J. Med. 385, 2036–2046 (2021). This study reports the results from a randomized and multicentre phase III clinical trial that showed the safety and efficacy of HIF2α inhibitor belzutifan as a treatment for RCC and non-RCC neoplasms in patients with VHL disease.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kamihara, J. et al. Belzutifan, a potent HIF2alpha inhibitor, in the pacak-zhuang syndrome. N. Engl. J. Med. 385, 2059–2065 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Choueiri, T. K. & Kaelin, W. G. Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat. Med. 26, 1519–1530 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Salman, S. et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. J. Clin. Invest. 132, e156774 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pullamsetti, S. S., Mamazhakypov, A., Weissmann, N., Seeger, W. & Savai, R. Hypoxia-inducible factor signaling in pulmonary hypertension. J. Clin. Invest. 130, 5638–5651 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhang, J. et al. HIF-1alpha and HIF-2alpha redundantly promote retinal neovascularization in patients with ischemic retinal disease. J. Clin. Invest. 131, e139202 (2021). This article provides evidence that targeting both HIF1α and HIF2α is necessary to prevent retinal neovascularization in patients with sickle cell retinopathy.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Dengler, V. L., Galbraith, M. & Espinosa, J. M. Transcriptional regulation by hypoxia inducible factors. Crit. Rev. Biochem. Mol. Biol. 49, 1–15 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Semenza, G. L. Pharmacologic targeting of hypoxia-inducible factors. Annu. Rev. Pharmacol. Toxicol. 59, 379–403 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Diao, X. et al. Identification of oleoylethanolamide as an endogenous ligand for HIF-3alpha. Nat. Commun. 13, 2529 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wu, D., Potluri, N., Lu, J., Kim, Y. & Rastinejad, F. Structural integration in hypoxia-inducible factors. Nature 524, 303–308 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12, 5447–5454 (1992).

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Tian, H., McKnight, S. L. & Russell, D. W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11, 72–82 (1997). This study reports the identification of EPAS1/HIF2α as an important player in vascularization.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Mastrogiannaki, M., Matak, P. & Peyssonnaux, C. The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood 122, 885–892 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Knutson, A. K., Williams, A. L., Boisvert, W. A. & Shohet, R. V. HIF in the heart: development, metabolism, ischemia, and atherosclerosis. J. Clin. Invest. 131, e137557 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B. & Simon, M. C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell Biol. 23, 9361–9374 (2003).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Takeda, N. et al. Differential activation and antagonistic function of HIF-alpha isoforms in macrophages are essential for NO homeostasis. Genes Dev. 24, 491–501 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Branco-Price, C. et al. Endothelial cell HIF-1alpha and HIF-2alpha differentially regulate metastatic success. Cancer Cell 21, 52–65 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Makino, Y. et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414, 550–554 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H. & Poellinger, L. Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the hypoxia-inducible factor-3alpha locus. J. Biol. Chem. 277, 32405–32408 (2002).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Semenza, G. L. The genomics and genetics of oxygen homeostasis. Annu. Rev. Genomics Hum. Genet. 21, 183–204 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • McNeill, L. A. et al. Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem. J. 367, 571–575 (2002).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Freedman, S. J. et al. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc. Natl Acad. Sci. USA 99, 5367–5372 (2002). This report provides the solution structure as a mechanism of the specific recognition of CBP–p300 by HIF1α.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhang, N. et al. The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism. Cell Metab. 11, 364–378 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hirota, K. HIF-alpha prolyl hydroxylase inhibitors and their implications for biomedicine: a comprehensive review. Biomedicines 9, 468 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999). This study shows that VHL tumour suppressor gene product pVHL is important for oxygen-dependent degradation of HIFα.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Iwai, K. et al. Identification of the von Hippel–Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl Acad. Sci. USA 96, 12436–12441 (1999).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Schofield, C. J. & Ratcliffe, P. J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 338, 617–626 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kasper, L. H. et al. Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression. EMBO J. 24, 3846–3858 (2005).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wenger, R. H., Stiehl, D. P. & Camenisch, G. Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005, re12 (2005).

    Article 
    PubMed 

    Google Scholar     

  • Hartmann, H. et al. Hypoxia-independent activation of HIF-1 by Enterobacteriaceae and their siderophores. Gastroenterology 134, 756–767 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Appelhoff, R. J. et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279, 38458–38465 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Yeh, T. L. et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem. Sci. 8, 7651–7668 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Markolovic, S., Wilkins, S. E. & Schofield, C. J. Protein hydroxylation catalyzed by 2-oxoglutarate-dependent oxygenases. J. Biol. Chem. 290, 20712–20722 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hodges, V. M., Rainey, S., Lappin, T. R. & Maxwell, A. P. Pathophysiology of anemia and erythrocytosis. Crit. Rev. Oncol. Hematol. 64, 139–158 (2007).

    Article 
    PubMed 

    Google Scholar     

  • Dame, C. et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92, 3218–3225 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhang, Y. et al. Erythropoietin action in stress response, tissue maintenance and metabolism. Int. J. Mol. Sci. 15, 10296–10333 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Obara, N. et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood 111, 5223–5232 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Souma, T., Suzuki, N. & Yamamoto, M. Renal erythropoietin-producing cells in health and disease. Front. Physiol. 6, 167 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Haase, V. H. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int. Suppl. 11, 8–25 (2021).

    Article 

    Google Scholar     

  • Macdougall, I. C. et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 81, 727–732 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Warnecke, C. et al. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J. 18, 1462–1464 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Flamme, I. et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects. PLoS ONE 9, e111838 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kapitsinou, P. P. et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood 116, 3039–3048 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Minamishima, Y. A. & Kaelin, W. G. Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science 329, 407 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Peyssonnaux, C. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J. Clin. Invest. 117, 1926–1932 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Qian, Z. M. et al. Divalent metal transporter 1 is a hypoxia-inducible gene. J. Cell Physiol. 226, 1596–1603 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Taylor, M. et al. Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 140, 2044–2055 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Singh, A. K. et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N. Engl. J. Med. 385, 2313–2324 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Singh, A. K. et al. Daprodustat for the treatment of anemia in patients undergoing dialysis. N. Engl. J. Med. 385, 2325–2335 (2021). This study reports the results from a randomized phase III clinical trial that demonstrated that HIF-PHDi daprodustat was noninferior to ESAs in cardiovascular safety and efficacy in correcting anaemia in patients with CKD undergoing dialysis.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Koeppen, M. et al. Hypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury. Nat. Commun. 9, 816 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K., Bonney, S. K. & Eckle, T. Attenuating myocardial ischemia by targeting A2B adenosine receptors. Trends Mol. Med. 19, 345–354 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Bowser, J. L., Phan, L. H. & Eltzschig, H. K. The hypoxia-adenosine link during Intestinal Inflammation. J. Immunol. 200, 897–907 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Vohwinkel, C. U., Hoegl, S. & Eltzschig, H. K. Hypoxia signaling during acute lung injury. J. Appl. Physiol. 119, 1157–1163 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eckle, T. et al. Identification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J. Immunol. 192, 1249–1256 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Vohwinkel, C. U. et al. HIF1A-dependent induction of alveolar epithelial PFKFB3 dampens acute lung injury. JCI Insight 7, e157855 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhao, C. et al. Deficiency of HIF-1alpha enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells. Emerg. Microbes Infect. 9, 691–706 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • McClendon, J. et al. Hypoxia-inducible factor 1alpha signaling promotes repair of the alveolar epithelium after acute lung injury. Am. J. Pathol. 187, 1772–1786 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Gong, H. et al. HIF2alpha signaling inhibits adherens junctional disruption in acute lung injury. J. Clin. Invest. 125, 652–664 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Jiang, X. et al. Endothelial hypoxia-inducible factor-2alpha is required for the maintenance of airway microvasculature. Circulation 139, 502–517 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Colgan, S. P., Furuta, G. T. & Taylor, C. T. Hypoxia and innate immunity: keeping up with the HIFsters. Annu. Rev. Immunol. 38, 341–363 (2020). This is an authoritative review on the importance of HIF in the regulation of innate immunity.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Palazon, A., Goldrath, A. W., Nizet, V. & Johnson, R. S. HIF transcription factors, inflammation, and immunity. Immunity 41, 518–528 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Taylor, C. T. & Scholz, C. C. The effect of HIF on metabolism and immunity. Nat. Rev. Nephrol. 18, 573–587 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • McGettrick, A. F. & O’Neill, L. A. J. The role of HIF in immunity and inflammation. Cell Metab. 32, 524–536 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Berg, N. K. et al. Hypoxia-inducible factor-dependent induction of myeloid-derived netrin-1 attenuates natural killer cell infiltration during endotoxin-induced lung injury. FASEB J. 35, e21334 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wu, G. et al. Hypoxia exacerbates inflammatory acute lung injury via the Toll-like receptor 4 signaling pathway. Front. Immunol. 9, 1667 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wing, P. A. C. et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Rep. 35, 109020 (2021). This is the first study to show the potential benefit of HIF-PHDi during SARS-CoV-2 infection.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wing, P. A. C. et al. Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. PLoS Pathog. 18, e1010807 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Nakamura, M., Imamura, T., Sobajima, M. & Kinugawa, K. Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia. Heart Vessels 38, 284–290 (2023).

    Article 
    PubMed 

    Google Scholar     

  • Wen, T., Zhang, X., Wang, Z. & Zhou, R. Hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with renal anemia: a meta-analysis of randomized trials. Nephron 144, 572–582 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Bartels, K., Karhausen, J., Clambey, E. T., Grenz, A. & Eltzschig, H. K. Perioperative organ injury. Anesthesiology 119, 1474–1489 (2013).

    Article 
    PubMed 

    Google Scholar     

  • Williams, G. W., Berg, N. K., Reskallah, A., Yuan, X. & Eltzschig, H. K. Acute respiratory distress syndrome: contemporary management and novel approaches during COVID-19. Anesthesiology 134, 270–282 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Gumbert, S. D. et al. Perioperative acute kidney injury. Anesthesiology 132, 180–204 (2020).

    Article 
    PubMed 

    Google Scholar     

  • Macdougall, I. C. New anemia therapies: translating novel strategies from bench to bedside. Am. J. Kidney Dis. 59, 444–451 (2012).

    Article 
    PubMed 

    Google Scholar     

  • Agrawal, D. et al. Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am. J. Nephrol. 53, 352–360 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Maxwell, P. H. & Eckardt, K. U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat. Rev. Nephrol. 12, 157–168 (2016). This is an authoritative review that discusses the advantages and challenges of using HIF-PHDis as treatment for renal anaemia.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Percy, M. J. et al. Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis. Blood 111, 5400–5402 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Percy, M. J. et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358, 162–168 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Percy, M. J. et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 103, 654–659 (2006).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Beck, J., Henschel, C., Chou, J., Lin, A. & Del Balzo, U. Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats. Int. J. Toxicol. 36, 427–439 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Provenzano, R. et al. Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials. Clin. J. Am. Soc. Nephrol. 16, 1190–1200 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kiriakidis, S. et al. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney Int. 92, 900–908 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Schejbel, L. et al. Molecular basis of hereditary C1q deficiency–revisited: identification of several novel disease-causing mutations. Genes Immun. 12, 626–634 (2011).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Fallah, J. & Rini, B. I. HIF inhibitors: status of current clinical development. Curr. Oncol. Rep. 21, 6 (2019).

    Article 
    PubMed 

    Google Scholar     

  • Aquino-Galvez, A. et al. Effects of 2-methoxyestradiol on apoptosis and HIF-1alpha and HIF-2alpha expression in lung cancer cells under normoxia and hypoxia. Oncol. Rep. 35, 577–583 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Gheorghiade, M., van Veldhuisen, D. J. & Colucci, W. S. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 113, 2556–2564 (2006).

    Article 
    PubMed 

    Google Scholar     

  • Zhang, H. et al. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc. Natl Acad. Sci. USA 105, 19579–19586 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Currie, G. M., Wheat, J. M. & Kiat, H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc. Med. J. 5, 130–135 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ren, X., Diao, X., Zhuang, J. & Wu, D. Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan. Mol. Pharmacol. 102, 240–247 (2022).

    Article 
    CAS 

    Google Scholar     

  • Rapisarda, A. et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62, 4316–4324 (2002).

    CAS 
    PubMed 

    Google Scholar     

  • Rapisarda, A. et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64, 1475–1482 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Welsh, S., Williams, R., Kirkpatrick, L., Paine-Murrieta, G. & Powis, G. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 3, 233–244 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jacoby, J. J. et al. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J. Thorac. Oncol. 5, 940–949 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Koh, M. Y. et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 7, 90–100 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Miranda, E. et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J. Am. Chem. Soc. 135, 10418–10425 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Burslem, G. M., Kyle, H. F., Nelson, A., Edwards, T. A. & Wilson, A. J. Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions. Chem. Sci. 8, 4188–4202 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Greenberger, L. M. et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7, 3598–3608 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zimmer, M. et al. Small-molecule inhibitors of HIF-2a translation link its 5′UTR iron-responsive element to oxygen sensing. Mol. Cell 32, 838–848 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhang, D. L., Ghosh, M. C. & Rouault, T. A. The physiological functions of iron regulatory proteins in iron homeostasis – an update. Front. Pharmacol. 5, 124 (2014).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Dai, Z. et al. Therapeutic targeting of vascular remodeling and right heart failure in pulmonary arterial hypertension with a HIF-2alpha inhibitor. Am. J. Respir. Crit. Care Med. 198, 1423–1434 (2018). This study reports the beneficial therapeutic effect of pharmacological HIF2α inhibitor C76 in rodent models of pulmonary hypertension.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Scheuermann, T. H. et al. Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106, 450–455 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Scheuermann, T. H. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol. 9, 271–276 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wehn, P. M. et al. Design and activity of specific hypoxia-inducible factor-2alpha (HIF-2alpha) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J. Med. Chem. 61, 9691–9721 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Courtney, K. D. et al. HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma. Clin. Cancer Res. 26, 793–803 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867–874 (2018). This study reports the results from a first-in-human phase I clinical trial indicating a favourable safety profile and activity of HIF2α inhibitor PT2385 in patients with heavily pretreated ccRCC.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Xu, R. et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2α (HIF-2α) inhibitor for the treatment of clear cell renal cell carcinoma. J. Med. Chem. 62, 6876–6893 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2alpha in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802–805 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • No authors listed. FDA OK’s HIF2α inhibitor belzutifan. Cancer Discov. 11, 2360–2361 (2021).

    Article 

    Google Scholar     

  • Wong, S. C. et al. HIF2alpha-targeted RNAi therapeutic inhibits clear cell renal cell carcinoma. Mol. Cancer Ther. 17, 140–149 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ma, Y. et al. HIF2 inactivation and tumor suppression with a tumor-directed RNA-silencing drug in mice and humans. Clin. Cancer Res. 28, 5405–5418 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Muz, B., de la Puente, P., Azab, F. & Azab, A. K. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3, 83–92 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Semenza, G. L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33, 207–214 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Rapisarda, A. et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64, 6845–6848 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ardizzoni, A. et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J. Clin. Oncol. 15, 2090–2096 (1997).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tibes, R. et al. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α. J. Clin. Oncol. 28, 3076–3076 (2010).

    Article 

    Google Scholar     

  • Jeong, W. et al. Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors. Cancer Chemother. Pharmacol. 73, 343–348 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wu, J. et al. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1alpha in advanced hepatocellular carcinoma. World J. Clin. Oncol. 10, 149–160 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).

    Article 

    Google Scholar     

  • Kasherman, L., Siu, D. H. W., Woodford, R. & Harris, C. A. Angiogenesis inhibitors and immunomodulation in renal cell cancers: the past, present, and future. Cancers 14, 1406 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pandey, A. K. et al. Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease. Hypertension 71, e1–e8 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kamba, T. & McDonald, D. M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 96, 1788–1795 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ganner, A. et al. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci. Rep. 11, 14827 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Battelli, C. & Cho, D. C. mTOR inhibitors in renal cell carcinoma. Therapy 8, 359–367 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Toschi, A., Lee, E., Gadir, N., Ohh, M. & Foster, D. A. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem. 283, 34495–34499 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Motzer, R. J. et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126, 4156–4167 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Raval, R. R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 25, 5675–5686 (2005).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Chen, W. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pelosci, A. LITESPARK-005 trial reveals PFS benefit of belzutifan in advanced RCC. Cancer Network, Home of the Journal ONCOLOGY (23 August 2023).

  • Stransky, L. A. et al. Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proc. Natl Acad. Sci. USA 119, e2120403119 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Davis, L. et al. Targeting HIF-2alpha in the tumor microenvironment: redefining the role of HIF-2alpha for solid cancer therapy. Cancers 14, 1259 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Feldman, D. R. et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1432–1439 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Redlich, A. et al. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children. Pediatr. Blood Cancer 68, e28981 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Yang, C. et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. J. Mol. Med. 93, 93–104 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922–930 (2012).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pacak, K. et al. New syndrome of paraganglioma and somatostatinoma associated with polycythemia. J. Clin. Oncol. 31, 1690–1698 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Yang, C. et al. Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121, 2563–2566 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wang, H. et al. A transgenic mouse model of Pacak–Zhuang syndrome with an EPAS1 gain-of-function mutation. Cancers 11, 667 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Maron, B. A. Revised definition of pulmonary hypertension and approach to management: a clinical primer. J. Am. Heart Assoc. 12, e029024 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • He, M. et al. Hypoxia induces the dysfunction of human endothelial colony-forming cells via HIF-1alpha signaling. Respir. Physiol. Neurobiol. 247, 87–95 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Shan, F., Li, J. & Huang, Q. Y. HIF-1 alpha-induced up-regulation of miR-9 contributes to phenotypic modulation in pulmonary artery smooth muscle cells during hypoxia. J. Cell Physiol. 229, 1511–1520 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zeng, Y. et al. Hypoxia inducible factor-1 mediates expression of miR-322: potential role in proliferation and migration of pulmonary arterial smooth muscle cells. Sci. Rep. 5, 12098 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Luo, Y. et al. CD146-HIF-1alpha hypoxic reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat. Commun. 10, 3551 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Tang, H. et al. Endothelial HIF-2alpha contributes to severe pulmonary hypertension due to endothelial-to-mesenchymal transition. Am. J. Physiol. Lung Cell Mol. Physiol. 314, L256–L275 (2018).

    PubMed 

    Google Scholar     

  • Hu, C. J. et al. Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension. Eur. Respir. J. 54, 1900378 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kim, Y. M. et al. Hypoxia-inducible factor-1alpha in pulmonary artery smooth muscle cells lowers vascular tone by decreasing myosin light chain phosphorylation. Circ. Res. 112, 1230–1233 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kojima, H. et al. Hypoxia-inducible factor-1 alpha deletion in myeloid lineage attenuates hypoxia-induced pulmonary hypertension. Physiol. Rep. 7, e14025 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Yu, Y. A. et al. Nonclassical monocytes sense hypoxia, regulate pulmonary vascular remodeling, and promote pulmonary hypertension. J. Immunol. 204, 1474–1485 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Cowburn, A. S. et al. HIF2alpha–arginase axis is essential for the development of pulmonary hypertension. Proc. Natl Acad. Sci. USA 113, 8801–8806 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Labrousse-Arias, D. et al. HIF-2alpha-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovasc. Res. 109, 115–130 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wang, S. et al. EPAS1 (endothelial PAS domain protein 1) orchestrates transactivation of endothelial ICAM1 (intercellular adhesion molecule 1) by small nucleolar RNA host gene 5 (SNHG5) to promote hypoxic pulmonary hypertension. Hypertension 78, 1080–1091 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tan, Q. et al. Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J. Biol. Chem. 288, 17134–17144 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Jiang, Y. et al. Topotecan prevents hypoxia-induced pulmonary arterial hypertension and inhibits hypoxia-inducible factor-1alpha and TRPC channels. Int. J. Biochem. Cell Biol. 104, 161–170 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ghosh, M. C. et al. Therapeutic inhibition of HIF-2alpha reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood 137, 2509–2519 (2021). This study shows the beneficial therapeutic effect of pharmacological HIF2α inhibitor belzutifan in a murine model of polycythaemia, pulmonary hypertension, pulmonary fibrosis and complications due to gain-of-function mutation of HIF2A.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Campochiaro, P. A. Ocular neovascularization. J. Mol. Med. 91, 311–321 (2013).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ozaki, H. et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest. Ophthalmol. Vis. Sci. 40, 182–189 (1999).

    CAS 
    PubMed 

    Google Scholar     

  • Kelly, B. D. et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074–1081 (2003).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Barben, M., Schori, C., Samardzija, M. & Grimm, C. Targeting Hif1a rescues cone degeneration and prevents subretinal neovascularization in a model of chronic hypoxia. Mol. Neurodegener. 13, 12 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Dioum, E. M., Clarke, S. L., Ding, K., Repa, J. J. & Garcia, J. A. HIF-2alpha-haploinsufficient mice have blunted retinal neovascularization due to impaired expression of a proangiogenic gene battery. Invest. Ophthalmol. Vis. Sci. 49, 2714–2720 (2008).

    Article 
    PubMed 

    Google Scholar     

  • Qin, Y. et al. PAI-1 is a vascular cell-specific HIF-2-dependent angiogenic factor that promotes retinal neovascularization in diabetic patients. Sci. Adv. 8, eabm1896 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zeng, M. et al. The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. J. Mol. Med. 95, 417–429 (2017).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Usui-Ouchi, A. et al. An allosteric peptide inhibitor of HIF-1alpha regulates hypoxia-induced retinal neovascularization. Proc. Natl Acad. Sci. USA 117, 28297–28306 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Miwa, Y. et al. Pharmacological HIF inhibition prevents retinal neovascularization with improved visual function in a murine oxygen-induced retinopathy model. Neurochem. Int. 128, 21–31 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Pan, X. & Lv, Y. Effects and mechanism of action of PX-478 in oxygen-induced retinopathy in mice. Ophthalmic Res. 63, 182–193 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Cheng, X. et al. Marked and rapid effects of pharmacological HIF-2alpha antagonism on hypoxic ventilatory control. J. Clin. Invest. 130, 2237–2251 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Macias, D. et al. HIF-2alpha is essential for carotid body development and function. eLife 7, e34681 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Cho, H. et al. On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539, 107–111 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Watts, E. R. & Walmsley, S. R. Inflammation and hypoxia: HIF and PHD isoform selectivity. Trends Mol. Med. 25, 33–46 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Lee, J. W. et al. Transcription-independent induction of ERBB1 through hypoxia-inducible factor 2A provides cardioprotection during ischemia and reperfusion. Anesthesiology 132, 763–780 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zuk, A. et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J. Pharmacol. Exp. Ther. 383, 11–24 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Li, J. et al. PMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORA2B signaling. J. Exp. Med. 218, e20210008 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ruan, W. et al. The hypoxia-adenosine link during myocardial ischemia-reperfusion injury. Biomedicines 10, 1939 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Conrad, C. & Eltzschig, H. K. Disease mechanisms of perioperative organ injury. Anesth. Analg. 131, 1730–1750 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hara, K., Takahashi, N., Wakamatsu, A. & Caltabiano, S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug. Metab. Pharmacokinet. 30, 410–418 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kansagra, K. A. et al. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin. Pharmacokinet. 57, 87–102 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Parmar, D. V. et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am. J. Nephrol. 49, 470–478 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Bottcher, M. et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br. J. Clin. Pharmacol. 84, 1557–1565 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Beck, H. et al. Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. ChemMedChem 13, 988–1003 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Czock, D. & Keller, F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin. Pharmacokinet. 61, 347–362 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Provenzano, R. et al. Oral hypoxia–inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin. J. Am. Soc. Nephrol. 11, 982–991 (2016).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Shibata, T. et al. Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male japanese subjects. Clin. Pharmacol. Drug. Dev. 8, 304–313 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Dhillon, S. Roxadustat: first global approval. Drugs 79, 563–572 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Provenzano, R. et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6-to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am. J. Kidney Dis. 67, 912–924 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Chen, N., Hao, C. & Liu, B. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis. J. Am. Soc. Nephrol. 29, B5 (2018).


    Google Scholar     

  • Besarab, A. et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. 27, 1225–1233 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Besarab, A. et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol. Dial. Transplant. 30, 1665–1673 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Chavan, A. et al. Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin. Pharmacol. Drug. Dev. 10, 950–958 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Nwogu, J. I. et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104, 2216–2221 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Xi, L., Taher, M., Yin, C., Salloum, F. & Kukreja, R. C. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1α and AP-1 and iNOS signaling. Am. J. Physiol. Heart Circ. Physiol. 287, H2369–H2375 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Bao, W. et al. Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat. J. Cardiovasc. Pharmacol. 56, 147–155 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Signore, P. E. et al. A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats. PLoS ONE 16, e0255022 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Philipp, S. et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur. J. Heart Fail. 8, 347–354 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Vogler, M. et al. Pre-and post-conditional inhibition of prolyl-4-hydroxylase domain enzymes protects the heart from an ischemic insult. Pflügers Arch. 467, 2141–2149 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Keränen, M. et al. Differential effects of pharmacological HIF preconditioning of donors versus recipients in rat cardiac allografts. Am. J. Transplant. 13, 600–610 (2013).

    Article 
    PubMed 

    Google Scholar     

  • Eckle, T., Köhler, D., Lehmann, R., El Kasmi, K. C. & Eltzschig, H. K. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation 118, 166–175 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Natarajan, R., Salloum, F. N., Fisher, B. J., Kukreja, R. C. & Fowler, A. A. III Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ. Res. 98, 133–140 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Natarajan, R. et al. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am. J. Physiol. Heart Circ. Physiol. 293, H1571–H1580 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ockaili, R. et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am. J. Physiol. Heart Circ. Physiol. 289, H542–H548 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhao, H.-X. et al. Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1α. Basic Res. Cardiol. 105, 109–118 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Huang, M. et al. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 118, S226–S233 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hyvärinen, J. et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia–reperfusion injury. J. Biol. Chem. 285, 13646–13657 (2010).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kerkelä, R. et al. Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. Mol. Cell. Biol. 33, 3321–3329 (2013).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hölscher, M. et al. Cardiomyocyte-specific prolyl-4-hydroxylase domain 2 knock out protects from acute myocardial ischemic injury. J. Biol. Chem. 286, 11185–11194 (2011).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Adluri, R. S. et al. Disruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1−/−) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1α transcription factor and its target genes in mice. Antioxid. Redox Signal. 15, 1789–1797 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Oriowo, B. et al. Targeted gene deletion of prolyl hydroxylase domain protein 3 triggers angiogenesis and preserves cardiac function by stabilizing hypoxia inducible factor 1 alpha following myocardial infarction. Curr. Pharm. Des. 20, 1305–1310 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Xie, L. et al. Depletion of PHD3 protects heart from ischemia/reperfusion injury by inhibiting cardiomyocyte apoptosis. J. Mol. Cell. Cardiol. 80, 156–165 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Deguchi, H. et al. Roxadustat markedly reduces myocardial ischemia reperfusion injury in mice. Circ. J. 84, 1028–1033 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhong, Z. et al. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G823–G832 (2008).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Harnoss, J. M. et al. Prolyl hydroxylase inhibition mitigates allograft injury during liver transplant. Transplantation 106, e430–e440 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Harnoss, J. M. et al. Prolyl hydroxylase inhibition enhances liver regeneration without induction of tumor growth. Ann. Surg. 265, 782–791 (2017).

    Article 
    PubMed 

    Google Scholar     

  • Schneider, M. et al. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology 138, 1143–1154 (2010). e1141–1142.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Liu, J. et al. Double knockdown of PHD1 and Keap1 attenuated hypoxia-induced injuries in hepatocytes. Front. Physiol. 8, 291 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Mollenhauer, M. et al. Deficiency of the oxygen sensor PHD1 augments liver regeneration after partial hepatectomy. Langenbecks Arch. Surg. 397, 1313–1322 (2012).

    Article 
    PubMed 

    Google Scholar     

  • Matsumoto, M. et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J. Am. Soc. Nephrol. 14, 1825–1832 (2003).

    Article 
    PubMed 

    Google Scholar     

  • Bernhardt, W. M. et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J. Am. Soc. Nephrol. 17, 1970–1978 (2006).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Xie, D. et al. Kidney-targeted delivery of prolyl hydroxylase domain protein 2 small interfering RNA with nanoparticles alleviated renal ischemia/reperfusion injury. J. Pharmacol. Exp. Ther. 378, 235–243 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jamadarkhana, P. et al. Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am. J. Nephrol. 36, 208–218 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Yang, Y. et al. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury. Clin. Sci. 132, 825–838 (2018).

    Article 
    CAS 

    Google Scholar     

  • Ito, M. et al. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. Kidney Int. 97, 687–701 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Bernhardt, W. et al. Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model. Proc. Natl Acad. Sci. USA 106, 21276–21281 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Tambuwala, M. M. et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139, 2093–2101 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Cummins, E. P. et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134, 156–165.e151 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tambuwala, M. M. et al. Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis. J. Control. Release 217, 221–227 (2015).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Manresa, M. C. et al. Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. Am. J. Physiol. Gastrointest. Liver Physiol. 311, G1076–G1090 (2016).

    Article 
    PubMed 

    Google Scholar     

  • Halligan, D. N. et al. Hypoxia-inducible factor hydroxylase inhibition enhances the protective effects of cyclosporine in colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 317, G90–G97 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Robinson, A. et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145–155 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Marks, E. et al. Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis. Inflamm. Bowel Dis. 21, 267–275 (2015).

    Article 
    PubMed 

    Google Scholar     

  • Keely, S. et al. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis. Mucosal Immunol. 7, 114–123 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Van Welden, S. et al. Haematopoietic prolyl hydroxylase‐1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis. J. Pathol. 241, 547–558 (2017).

    Article 
    PubMed 

    Google Scholar     

  • Okumura, C. Y. et al. A new pharmacological agent (AKB-4924) stabilizes hypoxia inducible factor-1 (HIF-1) and increases skin innate defenses against bacterial infection. J. Mol. Med. 90, 1079–1089 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zinkernagel, A. S., Peyssonnaux, C., Johnson, R. S. & Nizet, V. Pharmacologic augmentation of hypoxia-inducible factor—1α with mimosine boosts the bactericidal capacity of phagocytes. J. Infect. Dis. 197, 214–217 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Hirota, S. A. et al. Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology 139, 259–269.e253 (2010).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Schaible, B. et al. Hypoxia modulates infection of epithelial cells by Pseudomonas aeruginosa. PLoS ONE 8, e56491 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hirai, K., Furusho, H., Hirota, K. & Sasaki, H. Activation of hypoxia-inducible factor 1 attenuates periapical inflammation and bone loss. Int. J. Oral Sci. 10, 12 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wood, J. G. et al. Heme oxygenase‐1 upregulation following prolyl hydroxylase inhibition attenuates hypoxia‐induced microvascular inflammation. FASEB J. 23, 762.719 (2009).

    Article 

    Google Scholar     

  • Howard, J. M. et al. Upregulation of HIF-1 attenuates hemorrhagic shock/resuscitation-induced leukocyte adherence via an iNOS-dependent pathway. J. Am. Coll. Surg. 207, S39 (2008).

    Article 

    Google Scholar     

  • Figg, W. D. Jr. et al. Structural basis of prolyl hydroxylase domain inhibition by molidustat. ChemMedChem 16, 2082–2088 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wu, D. et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat. Chem. Biol. 15, 367–376 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wallace, E. M. et al. A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76, 5491–5500 (2016).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Haase, V. H. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial. Int. 21, S110–S124 (2017).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eckle, T. et al. Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J. 27, 3078–3089 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Aherne, C. M. et al. Coordination of ENT2-dependent adenosine transport and signaling dampens mucosal inflammation. JCI Insight 3, e121521 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ruan, W. et al. Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling. JCI Insight 8, e166011 (2023).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wang, G. L. & Semenza, G. L. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl Acad. Sci. USA 90, 4304–4308 (1993).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fraisl, P., Aragones, J. & Carmeliet, P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat. Rev. Drug. Discov. 8, 139–152 (2009).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Aragones, J. et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat. Genet. 40, 170–180 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ruan, W., Yuan, X. & Eltzschig, H. K. Circadian rhythm as a therapeutic target. Nat. Rev. Drug. Discov. 20, 287–307 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Semenza, G. L. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J. Bioenerg. Biomembr. 39, 231–234 (2007).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Carmeliet, P. et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485–490 (1998).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Forsythe, J. A. et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 16, 4604–4613 (1996).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Eltzschig, H. K., Weissmuller, T., Mager, A. & Eckle, T. Nucleotide metabolism and cell-cell interactions. Methods Mol. Biol. 341, 73–87 (2006).

    CAS 
    PubMed 

    Google Scholar     

  • Synnestvedt, K. et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993–1002 (2002).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ahmad, A. et al. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc. Natl Acad. Sci. USA 106, 10684–10689 (2009).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Morote-Garcia, J. C., Rosenberger, P., Kuhlicke, J. & Eltzschig, H. K. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood 111, 5571–5580 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Yuan, X. et al. Alternative adenosine receptor activation: the netrin-Adora2b link. Front. Pharmacol. 13, 944994 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Heck-Swain, K. L. et al. Myeloid hypoxia-inducible factor HIF1A provides cardio-protection during ischemia and reperfusion via induction of netrin-1. Front. Cardiovasc. Med. 9, 970415 (2022).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ohta, A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front. Immunol. 7, 109 (2016).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Choudhry, H. & Harris, A. L. Advances in hypoxia-inducible factor biology. Cell Metab. 27, 281–298 (2018).

    Article 
    CAS 
    PubMed 

    Google Scholar     

[ad_2]

Source link